Quick Answer
BioXcel Therapeutics, Inc. reported Total Revenue of $642.0 thousand for fiscal year 2025.
BioXcel Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $642.0K | -71.7% |
| 2024 | $2.27M | +64.2% |
| 2023 | $1.38M | +268.0% |
| 2022 | $375.0K | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $98.0K | -54.2% | -18.3% |
| June 30, 2025 | $120.0K | -89.1% | -28.6% |
| March 31, 2025 | $168.0K | -71.1% | -21.5% |
| September 30, 2024 | $214.0K | -37.2% | -80.6% |
| June 30, 2024 | $1.10M | +141.6% | +89.7% |
| March 31, 2024 | $582.0K | +182.5% | +70.7% |
| September 30, 2023 | $341.0K | +148.9% | -25.4% |
| June 30, 2023 | $457.0K | — | +121.8% |
- BioXcel Therapeutics, Inc. showed a decrease of -71.7% in Total Revenue compared to the prior fiscal year.
- Over the 2022–2025 period, BioXcel Therapeutics, Inc.’s total revenue has grown by 71.2% (from $375.0 thousand to $642.0 thousand).
- The most recent figure is from BioXcel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: